DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Intravenous (IV) Nitroglycerin for Versions in Nulliparous Women

Information source: University of Calgary
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Breech Presentation; Complication of Pregnancy

Intervention: IV Nitroglycerin (Drug); Normal saline (Drug)

Phase: N/A

Status: Completed

Sponsored by: University of Calgary

Official(s) and/or principal investigator(s):
Bruce B Allan, MD PhD, Principal Investigator, Affiliation: Calgary Health Region


Breech presentations (where a baby presents with feet or bottom down) have an increased risk of perinatal and neonatal complications, and are usually delivered by cesarean section. As an alternative, so that the baby can be delivered vaginally, an attempt can be made to turn the baby so that it is head down: this manoeuvre is called an external cephalic version (ECV). Drugs that relax the uterus (tocolytic agents) are sometimes used to help improve ECV success rates. Nitroglycerin is a tocolytic agent, but intravenous nitroglycerin has not been tested as an agent to help ECV. There is some suggestion that nitroglycerin may be more helpful in women who have not previously been pregnant (nulliparous women) than in women who have been pregnant more than once (multiparous women), and so we have planned two trials. This study is designed to answer the following questions for nulliparous women: Will administration of IV nitroglycerin for uterine relaxation improve ECV success rates? Will an increase in ECV success result in a decreased cesarean section rate?

Clinical Details

Official title: INVERT: IV Nitroglycerin for Versions Trial - a Randomized Placebo-controlled Trial in Nulliparous Women

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Success of ECV (ie fetus turned from Breech to cephalic) at the end of ECV procedure

Secondary outcome:

Success of ECV (ie fetus in cephalic presentation) at time of delivery

Mode of delivery

Maternal side effects and adverse events


Minimum age: N/A. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- any non-cephalic presentation

- singleton pregnancy

- >/= 37 weeks gestational age

- normal amniotic fluid volume

- reassuring fetal heart rate

Exclusion Criteria:

- labor

- ruptured membranes

- history of third trimester bleeding

- any pre-existing uterine scar

- pregnancy induced hypertension and gestational diabetes

- oligohydramnios and polyhydramnios

- intrauterine growth restriction or macrosomia

- hypotension or any serious medical illness

- inability to comprehend the consent form

Locations and Contacts

Foothills Medical Centre, Calgary, Alberta T2N 4J8, Canada

Peter Lougheed Centre, Calgary, Alberta, Canada

Rockyview Hospital, Calgary, Alberta, Canada

Additional Information

University of Calgary Department of Obstetrics and Gynaecology

Related publications:

Hilton J, Allan B, Swaby C, Wahba R, Jarrell J, Wood S, Ross S, Tran Q. Intravenous nitroglycerin for external cephalic version: a randomized controlled trial. Obstet Gynecol. 2009 Sep;114(3):560-7. doi: 10.1097/AOG.0b013e3181b05a19. Erratum in: Obstet Gynecol. 2009 Nov;114(5):1148. Wah, Raouf [corrected to Wahba, Raouf].

Starting date: March 2003
Last updated: August 27, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017